Abstract
The pharmacokinetics of flurbiprofen (ANSAID™) was evaluated in 25 patients with rheumatoid arthritis following an NSAID-free washout period. Statistically significant improvements were noted in pain, patient and physician global rating, Ritchie articular index, walk time, bead intubation coordinometry and zeta sedimentation rate. However, no statistically significant correlation was noted between these outcome measures and the primary pharmacokinetic parameters for S(+)-flurbiprofen (total plasma clearance, average steady state concentration, overnight trough plasma concentration). We conclude that the variability in the response to flurbiprofen cannot be accounted for on the basis of variability in the active drug concentrations in plasma for this racemic anti-inflammatory analgesic compound.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
